Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chang-An Jun-Tai Granule (肠安菌泰颗粒) is a Traditional Chinese Medicine (TCM) formulation developed for the treatment of irritable bowel syndrome with diarrhea (IBS-D). Developed by researchers at the Guangzhou University of Chinese Medicine, the drug is designed to address the core symptoms of IBS-D, including abdominal pain, urgency, and frequent loose stools. The formulation's name suggests a mechanism involving the stabilization of the intestinal environment and the modulation of gut microbiota. It has been evaluated in multicenter, randomized, placebo-controlled clinical trials to assess its efficacy and safety in improving stool consistency and reducing visceral hypersensitivity in patients with diarrhea-predominant IBS.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chang-An Jun-Tai Granule.